Drug maker Glenmark Pharma on Wednesday said it had received approval from the US health regulator for Arformoterol Tartrate Inhalation Solution, used to treat conditions like chronic bronchitis and ...
Zacks Investment Research on MSN
Here's why you should add Savara stock to your portfolio now
Savara SVRA continues to advance Molbreevi (molgramostim inhalation solution), its lead and only late-stage pipeline ...
Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received ...
MUMBAI, India, NAPLES, Fla, May 18, 2026 /PRNewswire/ -- Global pharmaceutical leader Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced that it ...
Perforomist is a solution formulation of the long-acting beta 2-agonist formoterol fumarate, which is administered by inhalation via nebulization. It acts as a bronchodilator by stimulating beta 2 ...
- LONHALA MAGNAIR is the first nebulized long-acting muscarinic antagonist (LAMA) approved for the treatment of COPD in the U.S. - MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc.
Ritedose Pharmaceuticals, a division of The Ritedose Corporation, has secured Food and Drug Administration approval for formoterol fumarate inhalation solution (20 mcg/2 ml). “The approval further ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. 1. Why am I using Atrovent Inhalation Solution? Atrovent Inhalation ...
As demonstrated in preclinical studies, the inhalation solution of ISM001-055 is well tolerated with good anti-fibrotic and anti-inflammatory efficacy, favorable safety and pharmacokinetic (PK) ...
HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...
CAMBRIDGE, Mass., April 28, 2026 /PRNewswire/ -- Insilico Medicine ( "Insilico", HKEX:3696 ), a clinical-stage, generative AI–driven drug discovery company, today announced that the inhalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results